Studies regarding impact of dosing intermittency on treatment efficacy in tuberculosis with isoniazid resistance
| Authors, year of publication | Measures of treatment efficacy | Source of study materials | Study design | Main findings | Strengths | Weaknesses | Risk of bias |
| Menzies et al, 200946 | Failure, relapse, acquired drug resistance | Multiple countries | Systematic review and meta-analysis* | Among TB patients with initial mono-resistance to isoniazid, partially intermittent treatment with daily initial phase reduces the rates of failure, relapses and acquired drug resistance. | The study clearly addressed a focused question with good coverage on methodology and assessment of study quality. Literature search was sufficiently rigorous. | There was considerable heterogeneity across studies. | Low |
| Escalante et al, 200147 | Relapse | USA | Retrospective cohort analysis | Twice-weekly treatment was associated with relapse among subjects with resistance to isoniazid. Thrice-weekly and daily treatment showed similar efficacy. | The study clearly addressed a focused question in a well-defined cohort. Outcomes were clearly defined, with reliable assessment of exposure. | Assessment of outcome was not blind. No comparison was made between participants and non-participants. Main potential confounders were not considered. CIs were not provided. | High |
↵* Articles identified by the literature search and included in systematic reviews identified by the current review are shown in appendix 3 in the online supplement.
TB, tuberculosis.